{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:14:07Z","timestamp":1787764447748,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Severe cutaneous adverse drug reactions (SCARs) are life-threatening diseases, which are associated with <jats:italic>human leukocyte antigen<\/jats:italic> (<jats:italic>HLA<\/jats:italic>) risk variants. However, the low positive predictive values of <jats:italic>HLA<\/jats:italic> variants suggest additional factors influence disease susceptibility. Using dapsone hypersensitivity syndrome (DHS) as a paradigm for SCARs, we show that the DHS patients harbor a sex-related global reduction in blood NK cells, contributing to the higher incidence of reactions in females. Single-cell RNA sequencing revealed a decrease in the immunoregulatory <jats:italic>CD56<\/jats:italic>\n            <jats:sup>low<\/jats:sup>\n            <jats:italic>XCL1\/2<\/jats:italic>\n            <jats:sup>low<\/jats:sup> NK cell subset and an expansion of <jats:italic>CD56<\/jats:italic>\n            <jats:sup>high<\/jats:sup>\n            <jats:italic>XCL1\/2<\/jats:italic>\n            <jats:sup>high<\/jats:sup> NK cell subsets with an effector phenotype in DHS patients compared to dapsone-tolerant individuals. Functionally, interleukin-15 superagonist-induced activation of NK cells exacerbated SCARs-like symptoms in a murine model. Mechanistically, TSC22 domain family member 3 (TSC22D3) deficiency enhanced NK cell effector function, shifting the immune response from CD4+\u2009T cell to CD8+\u2009T cell function. These results demonstrate that TSC22D3-regulated NK cells play a critical role in predisposing to drug hypersensitivity reactions, bridging innate and adaptive immune dysregulation in SCARs pathogenesis. Our study highlights the importance of NK cell heterogeneity and TSC22D3 in immune-mediated hypersensitivity disorders, offering potential therapeutic targets for SCARs and related conditions.<\/jats:p>","DOI":"10.1038\/s41392-025-02300-0","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:56:11Z","timestamp":1750478171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TSC22 domain family member 3 links natural killer cells to CD8+\u2009T cell-mediated drug hypersensitivity"],"prefix":"10.1038","volume":"10","author":[{"given":"Lele","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-2471","authenticated-orcid":false,"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiting","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-108X","authenticated-orcid":false,"given":"Joshua","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Naisbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-2075","authenticated-orcid":false,"given":"Xiaoli","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2300_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.16316","volume":"80","author":"R Cadot","year":"2025","unstructured":"Cadot, R. et al. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology. Allergy 80, 47\u201362 (2025).","journal-title":"Allergy"},{"key":"2300_CR2","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1056\/NEJMra2204547","volume":"391","author":"D Kroshinsky","year":"2024","unstructured":"Kroshinsky, D., Cardones, A. R. G. & Blumenthal, K. G. Drug Reaction with Eosinophilia and Systemic Symptoms. N. Engl. J. Med. 391, 2242\u20132254 (2024).","journal-title":"N. Engl. J. Med"},{"key":"2300_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40257-023-00779-3","volume":"24","author":"R Parisi","year":"2023","unstructured":"Parisi, R. et al. Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management. Am. J. Clin. Dermatol 24, 557\u2013575 (2023).","journal-title":"Am. J. Clin. Dermatol"},{"key":"2300_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-med-050913-022745","volume":"66","author":"R Pavlos","year":"2015","unstructured":"Pavlos, R. et al. T cell-mediated hypersensitivity reactions to drugs. Annu Rev. Med. 66, 439\u2013454 (2015).","journal-title":"Annu Rev. Med"},{"key":"2300_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/529382","volume":"46","author":"M Saag","year":"2008","unstructured":"Saag, M. et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111\u20131118 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"2300_CR6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","volume":"369","author":"FR Zhang","year":"2013","unstructured":"Zhang, F. R. et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369, 1620\u20131628 (2013).","journal-title":"N. Engl. J. Med"},{"key":"2300_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","volume":"155","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. JAMA Dermatol 155, 666\u2013672 (2019).","journal-title":"JAMA Dermatol"},{"key":"2300_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11396-2","volume":"10","author":"RY Pan","year":"2019","unstructured":"Pan, R. Y. et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat. Commun. 10, 3569 (2019).","journal-title":"Nat. Commun."},{"key":"2300_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"TM Ko","year":"2011","unstructured":"Ko, T. M. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128, 1266\u20131276.e11 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2300_CR10","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1172\/JCI99321","volume":"128","author":"M Cardone","year":"2018","unstructured":"Cardone, M. et al. A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. J. Clin. Invest 128, 2819\u20132832 (2018).","journal-title":"J. Clin. Invest"},{"key":"2300_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jid.2022.10.009","volume":"143","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. TAP2 Drives HLA-B *13:01\u2012Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity. J. Invest Dermatol 143, 722\u2013730 e1 (2023).","journal-title":"J. Invest Dermatol"},{"key":"2300_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/all.16393","volume":"80","author":"L Sun","year":"2025","unstructured":"Sun, L. et al. Feedback regulation of VISTA and Treg by TNF-alpha controls T cell responses in drug allergy. Allergy 80, 1400\u20131416 (2025).","journal-title":"Allergy"},{"key":"2300_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157962","volume":"132","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Cytometric analysis reveals an association between allergen-responsive natural killer cells and human peanut allergy. J. Clin. Invest 132, e157962 (2022).","journal-title":"J. Clin. Invest"},{"key":"2300_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2013.07.030","volume":"132","author":"G Deniz","year":"2013","unstructured":"Deniz, G., van de Veen, W. & Akdis, M. Natural killer cells in patients with allergic diseases. J. Allergy Clin. Immunol. 132, 527\u2013535 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2300_CR15","doi-asserted-by":"publisher","first-page":"eaay1005","DOI":"10.1126\/scitranslmed.aay1005","volume":"12","author":"MR Mack","year":"2020","unstructured":"Mack, M. R. et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci. Transl. Med. 12, eaay1005 (2020).","journal-title":"Sci. Transl. Med"},{"key":"2300_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaad.2020.06.032","volume":"84","author":"J You","year":"2021","unstructured":"You, J. et al. Dynamic cytokine profiles combined with enzyme-linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome. J. Am. Acad. Dermatol 84, 814\u2013816 (2021).","journal-title":"J. Am. Acad. Dermatol"},{"key":"2300_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","volume":"26","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat. Med. 26, 236\u2013243 (2020).","journal-title":"Nat. Med"},{"key":"2300_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","volume":"635","author":"TM Nordmann","year":"2024","unstructured":"Nordmann, T. M. et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. Nature 635, 1001\u20131009 (2024).","journal-title":"Nature"},{"key":"2300_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2023216118","volume":"118","author":"Z Huang","year":"2021","unstructured":"Huang, Z. et al. Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. Proc. Natl Acad. Sci. USA 118, e2023216118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2300_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41590-023-01463-8","volume":"24","author":"MI Cheng","year":"2023","unstructured":"Cheng, M. I. et al. The X-linked epigenetic regulator UTX controls NK cell-intrinsic sex differences. Nat. Immunol. 24, 780\u2013791 (2023).","journal-title":"Nat. Immunol."},{"key":"2300_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/0253-7184.120545","volume":"34","author":"AJ Lokhande","year":"2013","unstructured":"Lokhande, A. J., Sutaria, A., Shah, B. J. & Shah, A. N. Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011. Indian J. Sex. Transm. Dis. AIDS 34, 113\u2013118 (2013).","journal-title":"Indian J. Sex. Transm. Dis. AIDS"},{"key":"2300_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/annrheumdis-2017-212905","volume":"77","author":"SF Keller","year":"2018","unstructured":"Keller, S. F. et al. Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Ann. Rheum. Dis. 77, 1187\u20131193 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2300_CR23","doi-asserted-by":"publisher","first-page":"E1070","DOI":"10.1503\/cmaj.190339","volume":"191","author":"C Yokose","year":"2019","unstructured":"Yokose, C. et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ 191, E1070\u2013E1077 (2019).","journal-title":"CMAJ"},{"key":"2300_CR24","doi-asserted-by":"publisher","first-page":"881.e1","DOI":"10.1016\/j.cmi.2021.11.021","volume":"28","author":"P Bosch-Nicolau","year":"2022","unstructured":"Bosch-Nicolau, P. et al. Association of HLA-B *35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease. Clin. Microbiol Infect. 28, 881.e1\u2013881.e5 (2022).","journal-title":"Clin. Microbiol Infect."},{"key":"2300_CR25","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1097\/JTO.0b013e31822e722f","volume":"6","author":"B Eguia","year":"2011","unstructured":"Eguia, B. et al. Skin toxicities compromise prolonged pemetrexed treatment. J. Thorac. Oncol. 6, 2083\u20132089 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"2300_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijstd.ijstd_44_21","volume":"44","author":"B Singh","year":"2023","unstructured":"Singh, B. et al. A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine). Indian J. Sex. Transm. Dis. AIDS 44, 6\u201310 (2023).","journal-title":"Indian J. Sex. Transm. Dis. AIDS"},{"key":"2300_CR27","first-page":"693","volume":"59","author":"DE Rowlands","year":"1987","unstructured":"Rowlands, D. E. Harmless cutaneous reactions associated with the use of atracurium. A Rep. 1200 anaesthetics. Br. J. Anaesth. 59, 693\u2013696 (1987).","journal-title":"A Rep. 1200 anaesthetics. Br. J. Anaesth."},{"key":"2300_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet, L. et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat. Immunol. 25, 1474\u20131488 (2024).","journal-title":"Nat. Immunol."},{"key":"2300_CR29","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251.e20 (2023).","journal-title":"Cell"},{"key":"2300_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440, 890\u2013895 (2006).","journal-title":"Nature"},{"key":"2300_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12929-022-00845-8","volume":"29","author":"H Jiang","year":"2022","unstructured":"Jiang, H. et al. Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. J. Biomed. Sci. 29, 58 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2300_CR32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/all.13769","volume":"74","author":"Q Zhao","year":"2019","unstructured":"Zhao, Q. et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy 74, 1533\u20131548 (2019).","journal-title":"Allergy"},{"key":"2300_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jaci.2014.09.041","volume":"135","author":"CH Lin","year":"2015","unstructured":"Lin, C. H. et al. Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. J. Allergy Clin. Immunol. 135, 1063\u20131065.e5 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2300_CR34","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","volume":"129","author":"CY Wei","year":"2012","unstructured":"Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T. & Hung, S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129, 1562\u20139.e5 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2300_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011901","volume":"18","author":"A de Araujo","year":"2024","unstructured":"de Araujo, A. et al. Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy. PLoS Negl. Trop. Dis. 18, e0011901 (2024).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2300_CR36","doi-asserted-by":"publisher","first-page":"1483919","DOI":"10.3389\/falgy.2024.1483919","volume":"5","author":"JA Gutierrez-Brito","year":"2024","unstructured":"Gutierrez-Brito, J. A. et al. Sex hormones and allergies: exploring the gender differences in immune responses. Front Allergy 5, 1483919 (2024).","journal-title":"Front Allergy"},{"key":"2300_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.anai.2024.12.005","volume":"134","author":"L Jin","year":"2025","unstructured":"Jin, L., Ge, J., Cheng, Y., Deng, D. & Wan, P. Worldwide prevalence of atopic dermatitis in children between 2000 and 2021: A systematic analysis. Ann. Allergy Asthma Immunol. 134, 603\u2013609.e6 (2025).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2300_CR38","doi-asserted-by":"publisher","first-page":"eadd3085","DOI":"10.1126\/sciimmunol.add3085","volume":"9","author":"DE Ochayon","year":"2024","unstructured":"Ochayon, D. E. et al. Progressive accumulation of hyperinflammatory NKG2D(low) NK cells in early childhood severe atopic dermatitis. Sci. Immunol. 9, eadd3085 (2024).","journal-title":"Sci. Immunol."},{"key":"2300_CR39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633\u2013640 (2001).","journal-title":"Trends Immunol."},{"key":"2300_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28799-3","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nat. Commun. 13, 1158 (2022).","journal-title":"Nat. Commun."},{"key":"2300_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/all.14983","volume":"77","author":"Y Mitamura","year":"2022","unstructured":"Mitamura, Y. et al. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients. Allergy 77, 595\u2013608 (2022).","journal-title":"Allergy"},{"key":"2300_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","volume":"119","author":"L Le Cleach","year":"2000","unstructured":"Le Cleach, L. et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin. Exp. Immunol. 119, 225\u2013230 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"2300_CR43","first-page":"267","volume":"60","author":"JH Richardus","year":"1989","unstructured":"Richardus, J. H. & Smith, T. C. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr. Rev. 60, 267\u2013273 (1989).","journal-title":"Lepr. Rev."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02300-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T05:01:41Z","timestamp":1750482101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02300-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}